Opendata, web and dolomites

CardioProtectMI SIGNED

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Total Cost €


EC-Contrib. €






 CardioProtectMI project word cloud

Explore the words cloud of the CardioProtectMI project. It provides you a very rough idea of what is the project "CardioProtectMI" about.

resolution    medium    generation       reported    guidelines    tissue    deaths    injury    10    therapeutics    consequence    death    positioning    plan    survival    biotechnology    ihd    mitigate    restoration    stopping    mi    inflammation    myocardial    improvement    blood    mortality    chronic    failed    prepare    market    incidence    emerged    congestive    resother    first    class    reperfusion    candidate    anti    models    cell    reveal    tissues    strategies    rate    efficacy    human    peptide    flow    12    engage    opportunity    provider    date    infarction    severe    therapies    prove    validation    effect    14    utmost    therapy    acute    serious    later    recommend    pharma    clinical    smei    52    million    damage    procedure    humans    disease    stakeholders    trials    treatments    400    causing    cardio    ensuing    safety    drugs    innovation    strategic    supporting    readiness    inflammatory    itself    animal    protective    decreases    therapeutic    business    heart    alone    aps    drug    ischaemic    company    stages   

Project "CardioProtectMI" data sheet

The following table provides information about the project.


Organization address
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESOTHER PHARMA APS DK (KOBENHAVN) coordinator 50˙000.00


 Project objective

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOPROTECTMI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOPROTECTMI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More